Wiley gives hematology book new look

Share this article:
John Wiley & Sons is giving its American Journal of Hematology a fresh look, along with a nod to the open access publishing movement, in hopes of winning over younger authors.

The redesign, the first for the 30-year-old journal, coincides with the arrival of new editor-in-chief Carlo Brugnara, MD, who takes over from the title’s founder, Dr. Ananda Prasad. The monthly’s new look is intended to signal further changes to come. The old cover, said Wiley VP publishing director for medicine Shawn Morton, “could not have been much less appealing or timely. It was practically wearing bell bottoms.”

The new features will be phased in over 18 months, said Morton. Meanwhile, online archives are available dating back to 1996. “Issues of openness and access pervade scientific, medical and technical publishing these days,” says Morton.

The magazine’s online strategy includes aggressively posting material as it becomes available. It’s part of a bid to woo younger authors impatient with the slow-moving world of print media. “So we can say to authors, ‘Publish with us, and your content will be online, toot sweet. Younger people who place a premium on that may want to come to us.”

While the title does not currently have any affiliations with medical societies, Wiley is exploring content partnerships with several. “Maybe some of those relationships will evolve if we do it right,” says Morton.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...